Search Browse Earnings

Cartesian Therapeutics, Inc.

Nasdaq:RNAC

Pharmaceutical Preparations·FREDERICK, MD

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Brunn Carsten

CFO

Davis Blaine

Revenue

$38.3M

+47.2% YoY

FY 2025

Adj. EBITDA

-$42.7M

-111.6% margin

FY 2025

Net Income

-$77.4M

-202.3% margin

FY 2025

EPS (Diluted)

-$4.49

FY 2025

Stock Price

$8.34

-7.2%

2026-03-11

52W Range

$5.98 – $18.80

P/E Ratio

-1.9x

Market Cap

$221.1M

Cash

$212.6M

FY 2025

Total Debt

—

Net Cash

$212.6M

FY 2025

Enterprise Value

$8.5M

Debt / EBITDA

5.0x

FY 2025

EV / EBITDA

-0.2x

Employees

—